Oncology Corporate Profile
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|VAL-083||bi-functional alkylating agent||Refractory Glioblastoma Multiforme (GBM)||II|
|VAL-083||bi-functional alkylating agent||Frontline Glioblastoma Multiforme (GBM)||I|
|VAL-083||bi-functional alkylating agent||Non Small Cell Lung Cancer (NSCLC)||Preclinical|
|VAL-083||bi-functional alkylating agent||Ovarian cancer||Preclinical|
View additional information on product candidates here »